Keytruda™ (pembrolizumab) has recently been approved for use in Europe for advanced head and neck cancer following a major Phase-III clinical trial led by the Institute of Cancer Research (London, UK). Researchers also showed it was possible to predict which patients would respond well to the immunotherapy.
To view the full article, please register now for access